AstraZeneca upbeat on latest roxadustat trial data
11th Nov 2019 07:55
(Sharecast News) - AstraZeneca, along with its partner FibroGen, presented pooled efficacy and cardiovascular safety analyses from the pivotal phase 3 programme assessing 'roxadustat' on Monday, for the treatment of patients with anaemia from chronic kidney disease (CKD).
Read moreAstraZeneca reports positive trials for kidney drug
8th Nov 2019 07:50
(Sharecast News) - AstraZeneca on Friday reported clinical trials of its roxadustat drug for patients with anaemia from chronic kidney disease had significantly increased red haemoglobin levels.
Read moreThursday broker round-up
7th Nov 2019 13:28
(Sharecast News) - Associated British Foods: Goldman Sachs upgrades to buy with a target price of 2,750p.
Read moreAstraZeneca offloads Europe and Russia rights to 'Seroquel' medicines
30th Oct 2019 07:31
(Sharecast News) - AstraZeneca has agreed the sale and licence of the commercial rights to 'Seroquel' - quetiapine fumarate immediate release - and 'Seroquel XR' - quetiapine fumarate extended release - in Europe and Russia to Cheplapharm Arzneimittel, it announced on Wednesday.
Read moreLiberum upgrades AstraZeneca to 'buy' despite near-term premium
25th Oct 2019 13:23
(Sharecast News) - Analysts at Liberum upgraded their recommendation for shares of AstraZeneca, arguing that the consensus was - yet again - underestimating just how leveraged the firm was to its product pipeline.
Read moreFriday broker round-up
25th Oct 2019 12:56
(Sharecast News) - AstraZeneca: Liberum upgrades to buy with a target price of 8,250p.
Read moreAstraZeneca upgrades sales guidance after third quarter growth
24th Oct 2019 07:51
(Sharecast News) - AstraZeneca reported its year-to-date results following the end of its third quarter on Thursday, claiming that patients would benefit from further progress to its pipeline, while sales-growth momentum continued to drive its operating leverage.
Read moreFDA approves AstraZeneca drug for heart failure risk
21st Oct 2019 07:16
(Sharecast News) - AstraZeneca on Monday announced that its Farxiga treatment against heart failure risk in certain patient groups has received approval from the US Food and Drug Administration.
Read moreAstraZeneca breast cancer drug candidate clears FDA hurdle
17th Oct 2019 07:37
(Sharecast News) - AstraZeneca, alongside its partner Daiichi Sankyo Company, announced on Thursday that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for trastuzumab deruxtecan, or DS-8201, and granted it 'Priority Review' status.
Read moreTuesday broker round-up
15th Oct 2019 12:47
(Sharecast News) - Ocado: JP Morgan downgrades to underweight with a target price of 1,050p.
Read moreWednesday broker round-up
9th Oct 2019 12:51
(Sharecast News) - Volution Group: Peel Hunt upgrades to buy with a target price of 200p.
Read moreAstraZeneca asthma drug wins US regulatory approval for self-administration
4th Oct 2019 07:21
(Sharecast News) - AstraZeneca said on Friday that the US Food and Drug Administration has approved the self-administration of its Fasenra (benralizumab) for patients with severe eosinophilic asthma.
Read moreAstraZeneca offloads Losec rights, advances PT010 in US
1st Oct 2019 07:28
(Sharecast News) - AstraZeneca has agreed to sell the global commercial rights for Losec (omeprazole) and its associated brands, excluding China, Japan, the US and Mexico, to Cheplapharm Arzneimittel, it announced on Tuesday.
Read moreAstraZeneca upbeat on latest Tagrisso and Lynparza results
30th Sep 2019 09:20
(Sharecast News) - AstraZeneca released overall survival results from the phase 3 'FLAURA' trial of Tagrisso (osimertinib) in the first-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) on Monday.
Read moreAstraZeneca takes control of Linzess collaboration with Ironwood
18th Sep 2019 07:12
(Sharecast News) - AstraZeneca confirmed on Wednesday that it will take on responsibility for the development, manufacture and commercialisation of Linzess in China, Hong Kong and Macau after amending an agreement with Ironwood Pharmaceuticals.
Read more